The research in the Saltzman Lab is motivated by the desire to create safer and more effective medical and surgical therapy. We focus on tissue engineering and on creating better methods for drug delivery. Our group has developed technology based on the use of bio-compatible polymeric materials for the controlled delivery of drugs, proteins, and genes. We have also developed new polymeric materials that influence the growth and assembly of tissues.·

We are also committed to training a new generation of chemical and biomedical engineers. We believe in providing a stimulating and collaborative environment that promotes the free exchange of ideas and encourages creative blending of technology and modern biological science.


The practice of medicine has changed dramatically in our lifetimes, and even greater changes are anticipated in the next 20 years. Drug delivery is one area of substantial progress. Drugs have long been used to improve health and extend lives, but a number of new modes of drug delivery, which were made possible primarily through the work of biomedical engineers, have entered clinical practice recently. In addition, biomedical engineers have contributed substantially to our understanding of the physiological barriers to efficient drug delivery such as transport in the microcirculation and drug movement through cells and tissues.

Still, with all of this progress, many drugs—even drugs discovered using the most advanced molecular biology strategies—have unacceptable side effects. Side effects limit our ability to design drug treatments for cancer, neurodegenerative, and infectious diseases. Our laboratory is working on alternate strategy for drug delivery, which is based on physical targeting, or placement of the delivery system at the target site.

We are currently working on several drug delivery projects:

In vivo genomic editing of hematopoietic cells for HIV resistance, with Priti Kumar and Peter Glazer, supported by NIH.

Biodegradable Contraceptive Implants from Poly(ω-pentadecalactone-co-p-dioxanone) [poly(PDL-co-DO)], supported by FHI 360 under subcontracts from USAID and the Gates Foundation.

Nanoparticles  for intermediate- to long-term delivery of antiretroviral agents (ARVs), supported by CONRAD.

Polymer particles for slow release of GM-CSF to improve intrauterine embryo transfer, supported by Cooper Surgical.

Synthetic Nanoparticles for Gene Editing in the Brain in Utero, with Peter Glazer and David Stitelman, supported by The Brain Research Foundation.

CED of Nanoparticles Loading with Novel Agents for Improved Treatment of Gliomas, with Joseph Piepmeier, supported by NIH.

Targeted correction of the human CFTR gene, with Marie Egan and Peter Glazer, supported by NIH.

Multifunctional skin-adhesive nanoparticles for UV protection and anti-oxidant delivery, with Michael Girardi, supported by NIH through the Yale SPORE in Skin Cancer.


Tissue engineering is a new field of inquiry, defined about 20 years ago, but it is emerging as an option for certain patients. The field has grown rapidly from definition to the production of clinical products. Tissue engineering combines knowledge from the biological sciences with the materials and engineering sciences to develop new approaches to repair tissues, and to develop replacements for tissues. Tissue engineering thus involves a combination of disciplines to achieve new therapies and, in some cases, entirely new approaches to therapy.

We are currently working on several tissue engineering projects:

Optimizing Therapeutic Revascularization by Endothelial Cell Transplantation, with Jordan Pober, supported by NIH.

Research Interests

Drug Delivery
Gene Therapy
Tissue Engineering


Department of Biomedical Engineering  |  Yale University
Malone Engineering Center (map)
55 Prospect St.  |  New Haven, CT 06511

Vascular Biology & Therapeutics Program | Yale School of Medicine
Amistad Research Building (map)
10 Amistad St.  |  New Haven, CT 06520

For More Information

If you are interested in learning more about open positions in our lab, please e-mail Mark Saltzman.